2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

Abstract Number: 1633

Ulodesine (BCX4208) Add-On Therapy to Allopurinol 300mg Lowers Hypoxanthine and Xanthine Plasma Levels in a Dose-Dependent Fashion: Results From a 12-Week Randomized Controlled Trial in Patients with Gout
Abstract Number: 150

Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study
Abstract Number: 1351

Ultrasonographic Entheseal Abnormalities Among Patients with Psoriatic Arthritis, Psoriasis Alone and Healthy Individuals and Their Correlation with Disease-Related Variables
Abstract Number: 127

Ultrasonographic Evaluation of the Hands of Patients with Primary and Secondary Sjögren´s Syndrome
Abstract Number: 1379

Ultrasonographic Is More Sensitive Than Traditional Clinical Evaluation in the Detection of Hands and Wrists Synovitis and Digital Soft Tissue Involvement in Early Psoriatic Arthritis
Abstract Number: 2186

Ultrasonography of Major Salivary Glands in Primary Sjögren’s syndrome
Abstract Number: 126

Ultrasonography of Salivary Glands: Diagnostic and Prognostic Value in Primary Sjögren’s Syndrome
Abstract Number: 809

Ultrasonography Predicts Achievement of Deeper Remission After DAS28-Based Clinical Remission of Rheumatoid Arthritis
Abstract Number: 119

Ultrasound (US) Findings in Patients with Knee Pain: Sensitivity and Specificity for the Diagnosis of Knee Osteoarthritis and Development of an US Prediction Score
Abstract Number: 117

Ultrasound for Diagnosis of Carpal Tunnel Syndrome – Comparison of Different Methods to Determine Median Nerve Volume and Value of Power Doppler Sonography
Abstract Number: 111

Ultrasound Measurement of Metacarpal Cartilage Thickness Correlates with Joint Space Narrowing in the Metacarphalangeal Joints of Patients with Rheumatoid Arthritis
Abstract Number: 1044

Ultrasound Scores of Enthesitis and Dactylitis Do Not Correlate with Corresponding Clinical Findings in Psoriasis Arthritis
Abstract Number: 2636

Understanding Why Treat-to-Target Strategies Are Difficult to Follow
Abstract Number: 1460

Unmasking Latent Pulmonary Arterial Hypertension by Fluid Challenge in Patients with Systemic Sclerosis
Abstract Number: 658

Up-Regulation of A Disintegrin and Metalloprotease with Thrombospondin Type I Repeats-13 Correlates with Ischemic Cerebrovascular Disease in Systemic Lupus Erythematosus Patients
Abstract Number: 1529

Upper Airway Gene Expression Profiling in Granulomatosis with Polyangiitis
Abstract Number: 2065

Uptake of the American College of Rheumatology’s (ACR) Rheumatology Clinical Registry (RCR): Quality Measure Summary Data
Abstract Number: 2397

Urinary Biomarkers in Vasculitis Associated with Anti-Neutrophil Cytoplasmic Antibodies
Abstract Number: 628

Urinary Heparanase Activity Is Elevated in Patients with Lupus Nephritis and Correlate with Protein Excretion
Abstract Number: 839

Urinary Levels of High Mobility Group Box 1 Protein Are Elevated in Patients with Active Lupus Nephritis, and Correlate with Renal Histopathology
Abstract Number: 2474

Urine Biomarkers Distinguish Between Proliferative and Membranous Lupus Nephritis in Childhood Onset Systemic Lupus Erythematosus
Abstract Number: 2388

Urticarial Vasculitis: Clinical Study
Abstract Number: 114

US Examination of Wrists and Hands: A Comparison Between Rheumatoid Arthritis and Psoriatic Arthritis
Abstract Number: 2234

US Treatment Patterns of Psoriatic Arthritis Patients Newly Initiated On Etanercept or Adalimumab
Abstract Number: 377

Use and Long Term Use of Complementary and Alternative Medicine in Rheumatoid Arthritis Patients
Abstract Number: 526

Use of a Novel Probe to Demonstrate Granzyme B Activity in Sjogren’s Syndrome Salivary Glands
Abstract Number: 378

Use of Anti-Tumor Necrosis Factor Monotherapy and Adherence with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs in Combination with Anti-Tumor Necrosis Factor Therapy Among Rheumatoid Arthritis Patients in a Real-World Setting
Abstract Number: 1242

Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis
Abstract Number: 270

Use of Drug Combinations in Patients with Osteoarthritis: A Population-Based Cohort Study
Abstract Number: 523

Use of Global Gene Expression Profiling to Characterize Sjögren’s Patients Who Underexpress Interferon-Inducible Genes
Abstract Number: 54

Use of Health Plan Data to Assess Feasibility of Large Pragmatic Clinical Trials in Rheumatoid Arthritis
Abstract Number: 64

Use of Moist Snuff and the Risk of Developing Rheumatoid Arthritis; Results From the Swedish Epidemiological Investigation of Rheumatoid Arthritis Study
Abstract Number: 1145

Use of Non-Etanercept Biologics in Children with Juvenile Idiopathic Arthritis: Results From the Biologics for Children with Rheumatic Diseases Study
Abstract Number: 907

Use of Patient Preferences to Inform the Development of Disease Modifying Drugs for Osteoarthritis
Abstract Number: 925

Use of Rheumatology Services for Arthritis: The Role of SES and Geographic Availability of Rheumatologists and Primary Care Physicians
Abstract Number: 1909

Use of Uric Lowering Therapies within a Large Health Care System
Abstract Number: 293

Usefulness of Cardiac Magnetic Resonance in the Assessment of Myocardial Inflammation and Fibrosis in Children Born to Mothers with Anti-SSA/Ro Antibodies: A Prospective Study of 23 Cases and 6 Controls
Abstract Number: 685

Using a Library of Synthetic Autoantigen Mimics to Discover Biomarkers of Systemic Lupus Erythematosus
Abstract Number: 2060

Using the Electronic Medical Record to Increase Rates of Physician Assessment of Lipids in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Quality Improvement Initiative
Abstract Number: 2430

Using the Internet in Help-Seeking As Illness Develops in Early Rheumatoid Arthritis
Abstract Number: 569

Ustekinumab Improves Arthritis-Related and Skin-Related Quality of Life in Patients with Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized and Double Blinded Phase III Psummit I Trial
Abstract Number: 2557

Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Abstract Number: 2562

Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Psummit I Study
Abstract Number: 559

Utility of Dual-Energy X-Ray absorptiometry Scanning and Risk of Osteoporosis in Ankylosing Spondylitis; A Prospective Study
Abstract Number: 742

Utility of HLA-B5801 Genotyping and Renal Dosing of the Starting Dose of Allopurinol in Preventing Allopurinol Hypersensitivity Syndrome: A Cost-Effectiveness Analysis
Abstract Number: 716

Utility of Novel Patient-Reported Outcome Instruments in Predicting Cardiac Involvement and Pulmonary Hypertension in Patients with Systemic Sclerosis
Abstract Number: 133

Utility of PET-CT Imaging in IgG4-Related Disease
Abstract Number: 1970

Utility of Spine Bone Mineral Density in Fracture Prediction within the Fracture Risk Assessment Tool (FRAX)
Abstract Number: 2165

Utility of Vectra-DA™ On Assessment of Rheumatoid Arthritis Disease Activity and Golimumab Response: Results of a Pilot Study From a Phase 3 Trial in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
Abstract Number: 1834

Utilization and Expected Cost of Rheumatoid Arthritis Patients Treated with Golimumab: A Specialty Pharmacy Perspective
Abstract Number: 2039

Uveitis Surveillance Through Lean-Six Sigma for Quality Assurance in Juvenile Idiopathic Arthritis

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].